Parallel Advisors’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.96K Buy
123
+6
+5% +$222 ﹤0.01% 3125
2025
Q4
$4.93K Hold
117
﹤0.01% 2848
2025
Q3
$4.02K Hold
117
﹤0.01% 2860
2025
Q2
$3.16K Sell
117
-4,766
-98% -$138K ﹤0.01% 2900
2025
Q1
$145K Sell
4,883
-3,684
-43% -$140K ﹤0.01% 1106
2024
Q4
$339K Buy
8,567
+8,429
+6,108% +$319K 0.01% 724
2024
Q3
$4.7K Buy
138
+25
+22% +$703 ﹤0.01% 2632
2024
Q2
$2.45K Hold
113
﹤0.01% 2753
2024
Q1
$2.5K Sell
113
-24
-18% -$586 ﹤0.01% 2761
2023
Q4
$3.77K Hold
137
﹤0.01% 2605
2023
Q3
$3.06K Buy
137
+24
+21% +$617 ﹤0.01% 2684
2023
Q2
$2.88K Hold
113
﹤0.01% 2633
2023
Q1
$2.52K Hold
113
﹤0.01% 2684
2022
Q4
$2.68K Hold
113
﹤0.01% 2569
2022
Q3
$2K Sell
113
-17
-13% -$383 ﹤0.01% 2780
2022
Q2
$3K Buy
+130
New +$2.63K ﹤0.01% 2502
2022
Q1
Sell
-4
Closed 3288
2021
Q4
$0 Buy
+4
New +$177 ﹤0.01% 3304
2020
Q1
Sell
-790
Closed -$22K 2664
2019
Q4
$22K Hold
790
﹤0.01% 1363
2019
Q3
$19K Hold
790
﹤0.01% 1386
2019
Q2
$23K Buy
+790
New +$19.7K ﹤0.01% 1225

Other funds holding VCYT

Parallel Advisors's VCYT Position: Q1 2026 in Review

Parallel Advisors increased its Veracyte (VCYT) stake by 5.1% in Q1 2026, buying an estimated $222 and bringing the position to 123 shares worth $3.96K. The position accounts for ﹤0.01% of the portfolio, ranked #3125.

Parallel Advisors first reported a position in VCYT in Q2 2019 and has held it in 20 quarters since. The position peaked at $339K in Q4 2024. 334 funds tracked by Wall St. Rank hold VCYT as of Q1 2026.

  • Parallel Advisors held 123 shares of Veracyte worth $3.96K as of Q1 2026.
  • Parallel Advisors bought 6 Veracyte shares in Q1 2026, an estimated $222.
  • Veracyte made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3125 holding.
  • Parallel Advisors first reported a position in Veracyte in Q2 2019 and has held it in 20 quarters since.
  • Parallel Advisors's Veracyte position peaked at $339K in Q4 2024.
  • 334 funds tracked by Wall St. Rank held Veracyte as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.